Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Formato: Artículo
Lenguaje:English
Publicado: Adis, Springer Healthcare 2023-07-01
Colección:Rheumatology and Therapy
Materias:
Post-marketing surveillance
Psoriatic arthritis
Rheumatoid arthritis
Safety
Tofacitinib
Acceso en línea:https://doi.org/10.1007/s40744-023-00576-8

Internet

https://doi.org/10.1007/s40744-023-00576-8

Ejemplares similares